Glenmark gets USFDA approval for Clindamycin Phosphate Foam 1%

Glenmark


Chennai, Sep 21 : Pharma major Glenmark Pharmaceuticals Ltd on Tuesday said it has received final approval by the United States Food & Drug Administration (USFDA) for Clindamycin Phosphate Foam, 1 per cent, the generic version of Evoclin Foam, 1 per cent, of Mylan Pharmaceuticals Inc. According to IQVIA sales data for the 12 month period ending July 2021, the Evoclin Foam, 1 per cent, market achieved annual sales of approximately $12.0 million. Glenmark's current portfolio consists of 173 products authorized for distribution in the US marketplace and 47 ANDA's (Abbreviated New Drug Application) pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, the company said. /IANS




Related

100 cr vax is Diwali of Atmanirbhar Bharat: Mandaviya
[New Delhi: Union Health Minister Mansukh Mandaviya and Union Minister of State (MoS) for Health and Family Welfare Bharati Pravin Pawar show victory

California variant of Covid now in Pakistan
New Delhi, Oct 21 : Pakistan health authorities have announced that another variant of the deadly Covid virus had managed to reach Pakistan, Dawn repo

India logs 18,454 new Covid cases, recovery rate maintained at 98.15%
New Delhi, Oct 21 : India reported 18,454 fresh Covid-19 cases on Thursday, and 160 deaths in the last 24 hours, even as the recovery rate continues t